Exposures to infants and young children have been a prominent concern for the human health risk assessment of dioxins (Greene et al., 2003; USEPA, 2003) . These highly lipophilic and persistent compounds are transferred from mother to infant during breast-feeding and are known to be present in the fats of dairy products, meats, and other foods commonly consumed by young children (ATSDR, 1998) . The higher fat intake per body weight in younger children (e.g., ages 0-2 years) reinforces concerns that they receive considerably higher intake of dioxins per body weight compared to adults. Moreover, the greater hand-to-mouth contact rates among younger children may lead to intake of dioxins present in environmental sources such as contaminated soils (Greene et al., 2003; Paustenbach et al., 2006; USEPA, 2002a) . Accordingly, the combined impact of these higher potential exposures to dietary and environmental sources in young children and the associated health risks must be properly characterized and understood.
It is commonly assumed that children may be more sensitive to potential toxic effects of chemicals in general based on conservative choices for childhood exposure parameters in risk assessment (USEPA, 1989; Williams et al., 2003) and, especially, to chemicals with potential neurodevelopmental effects like lead and dioxins that are known to bioaccumulate in the human body (Greene et al., 2003; USEPA, 2002b USEPA, , 2003 . Bioaccumulation leads to potential hazards that are not well predicted by daily dose, but rather must be examined with respect to body burden or target organ/tissue concentration accumulated over time.
Fortunately, the general population body burdens of dioxins in developed countries have decreased over the past two decades (Aylward and Hays, 2002; Hays and Aylward, 2003; Lorber, 2002) . Indeed, general population body burden estimates for polychlorodibenzodioxins and polychlorodibenzofurans (PCDD/Fs), expressed in World Health Organization (WHO) toxic equivalents (TEQs), have been lowered more than an order of magnitude in the last 20 years. This downward trend is associated with the recognition of dioxin hazards in the 1970#s and the extensive interventions to limit emissions and exposures through research that characterized the prominent sources and through regulatory interventions and application of risk assessment principles (USEPA, 2003) . This trend is also important to consider in the assessment of total exposures and health risks of dioxins in young children since the body burdens present in reproductive-age women can create the baseline dioxin body burden in their offspring via in utero transfer and breast-feeding (Richter et al., 2006) . Further, it is expected that background dietary exposures to dioxins have been lowered concurrently with the observed decrease in general population body burdens.
Measurements of adipose and liver concentrations of 2,3,7,8-tetrachlorodibenzodioxin (TCDD) in infants have suggested that the relatively high daily TCDD doses associated with breast-feeding may not lead to the high body burdens predicted by toxicokinetic models using a constant half-life for all ages (Kreuzer et al., 1997) . Using a simple model that accommodated an age-dependent adipose tissue volume, Kreuzer et al. (1997) estimated that the half-life for TCDD in infants was only about 0.4 years, much shorter than the 7-11 years estimated for adults. Lorber and Phillips (2002) reported a modeling exercise of PCDD/F body burdens during breastfeeding of infants using a similar one-compartment model and including TCDD TEQ as TCDD. Leung et al. (2006) recently verified the half-life of TCDD in infants and identified similar short half-lives for other PCDD/F congeners (e.g., 0.2-0.5 years). The reasons for the shorter half-lives in young children are not fully understood, but might be due to a combination of factors, including the effect of dilution from the rapid growth of the adipose mass, higher fecal lipid excretion relative to adults, and increased metabolism (Kreuzer et al., 1997) . Recent observations that children and adolescents (under age 18 years) reduced their total TCDD burdens more readily than adults exposed during the Seveso incident, beyond those accounted for by growth-related dilution, suggest that excretion probably plays an important role . Our preliminary model (paustenbach et al., 2004) adapted the Kreuzer et al. (1997) model for TCDD to examine child body burdens of all relevant PCDD/Fs, and some of the limitations and needed refinements of these earlier models were analyzed by Kerger et al. (2007) . Like the Integrated Environmental Uptake Biokinetic Model (USEPA, 2002b) developed for evaluating childhood lead exposures, the age-dependent half-life model for childhood dioxin body burdens provides more accurate predictions of both peak and long-term average blood lipid concentrations which are almost certainly the best dose metric for predicting the adverse effects of the PCDD/Fs.
The purpose of this study is to describe an adaptable internal dose model for evaluating dietary and soil exposures to PCDD/ Fs in young children. Internal dose is defined here as being equivalent to the blood lipid concentration of dioxin TEQ. The model algorithms, data sets, parameters, and assumptions are fully described, and the implications of the model outputs and further refinements and applications are explored. et al. (2007) described our preliminary agedependent half-life model for all 2,3,7,8-chlorinated PCDD/Fs based on a modification of the toxicokinetic model for TCDD by Kreuzer et al. (1997) . Our preliminary model developed in (Kerger et al., 2007 used a similar framework to the current model but it lacked flexibility and much of the detailed assessment of empirical congener-specific pharmacokinetic parameters, monthly intake, and dose estimates corresponding to body size parameters for ages 0-2 and congener-specific relative bioavailability and doses from soil ingestion and dermal contact based on the probabilistic assessment of Paustenbach et al. (2006) . In the basic onecompartment model used here and by Kreuzer et al. (1997) , Lorber (2002) , and others, the distribution of dioxins in humans is assumed to be exclusively in the volume of total body fat. This volume expands substantially during childhood and tends to reduce the effective half-life of dioxins at early ages. An equilibrium is proposed to exist between ingested/ excreted dietary fats and the body burden of dioxins, particularly for infants and young children. Since breast-fed infants take in more dietary fat, and a greater proportion of dietary fat is excreted in the feces of these infants, the net body burden in infants may be attenuated compared to adults who do not experience the rapid growth rate and fat excretion seen in young children.
MODEL DESCRIPTION

Kerger
The model is comprised of four basic modules that characterize all the data inputs, assumptions, and algorithms for calculating two outputs: (1) the temporal pattern of blood lipid TEQ concentrations from birth through age 7 years and (2) the peak and TWA TEQ concentration. To simplify the calculations, congeners with the same WHO TEF value were combined (i.e., all 2,3,7,8-hexaCDD/Fs, all 2,3,7,8-heptaCDD/Fs, and OCDD/F). The two outputs can be incorporated into risk assessments and compared to appropriate "safe" internal dose benchmarks to be determined by scientific consensus as was the case for the Integrated Environmental Uptake Biokinetic Model for lead (USEPA, 2002b) .
Module 1: Child Body Size Parameters
Child body weight and body fat mass from birth through age 7 years are two necessary parameters for this toxicokinetic model. Recently updated 50th percentile body weights and body mass index (BMI) for children in the United States are utilized in the model (CDC, 2000) . Body fat percentages are estimated based on BMI by applying the age-and sex-specific equations derived by Deurenberg et al. (1991) . Data for male children are used in the model due to the leaner body fat percentage in males compared to females (CDC, 2000; ICRP, 1975) ; leaner body fat percentage corresponds mathematically to higher lipid PCDD/F concentrations in the model and hence is more conservative. Figure 1 illustrates the rapid rise in BMI and body fat percentage in male children during the first 7 months of life, followed by a plateau between ages 8 and 14 months and a decline to a leaner state that continues through about age 60 months (5 years). Early childhood obesity could CHILD DIOXIN INTERNAL DOSE MODEL 225 have competing effects of both diluting dioxin body burden (by increasing volume of distribution in fat) and lengthening elimination half-life (by sequestering dioxins in adipose), but the current model did not attempt to evaluate this issue.
Body fat mass was derived by multiplying the estimated agespecific male body fat percentage (Deurenberg et al., 1991) times the 50th percentile age-specific male child body weight (CDC, 2000) . Figure 2 illustrates the pattern of body fat mass (i.e., the estimated volume of distribution for PCDD/Fs) for an average male child in the United States through age 84 months (7 years). Consistent with the rapid increase in body fat percentage during the first year of life, body fat mass shows a steep rise during this age span, followed by a transition plateau between ages 1 and 2, and a more gradual and relatively linear rate of increase from about age 2.5-7 years (Fig. 2) . These age-dependent body fat mass parameters, based on recent data (CDC, 2000) , have important implications for the toxicokinetic model predictions.
The model default estimates for central tendency body size parameters for ages 0-2 years (monthly) and 2-7 years (at 6month intervals) are tabulated in the Supplementary Table A-1. Module 2: Child Dietary PCDD/F Intake Parameters Average daily intake rates for breast milk, formula, and other dietary items commonly ingested by children ages 0-7 years are integrated into the model. The model adopts an approach that integrates empirical measurements of average daily intake of breast milk (Dewey and Lonnerdal, 1983; Neville et al., 1988) expressed as grams of milk fat per kilogram body weight per day. A similar approach is applied to data reported for baby formula intake (Koletzko et al., 2000) . Figure 3 illustrates the pattern of fat intake from breast milk and formula during the first year of life when expressed as total intake (grams fat per day) and body weight-adjusted intake or dose (grams fat per kilogram body weight per day). Note that the degree of variability in estimated intake in fat grams per day during this rapid growth period is attenuated by normalizing the intake to age-specific body weight using the metric of fat grams per kilogram body weight per day ( Fig. 3 ).
FIG. 1. Male child: BMI and body fat percentage versus age from birth to 84 months. BMI based on 50th percentile values in charts reported by CDC (2000) and body fat percentage calculated from BMI based on sex-and agespecific equations of Deurenberg et al. (1991) . Adiposity reaches a peak around 7 months of age and gradually declines to a plateau after about 60 months of age.
FIG. 2. Male child: body fat mass versus age from birth to 84 months. Body fat mass based on body fat percentage times body weight for 50th percentile male child as reported by CDC (2000) . Body fat percentage calculated according to Deurenberg et al. (1991) . Adipose volume rises rapidly during the first 12-18 months of life, reaching a relative plateau at 18-24 months and then continuing to rise at a lesser rate from 24 to 84 months.
FIG. 3.
Breast milk fat and baby formula fat intake versus age from birth to 12 months. Fat intake rates for breast milk based on data reported by Dewey and Lonnerdal (1983) and Neville et al. (1988) as illustrated in Table A -2. Fat intake (g/day) from breast milk generally decreases with longer duration of fulltime breast-feeding, whereas intake from full-time formula feeding remains relatively constant. Fat intake normalized to infant body weight (g fat/kg body weight/day) shows a more uniform and gradually decreasing fat intake pattern for the first 12 months of full-time breast-feeding or full-time formula feeding.
The model also takes into account the nutritional recommendation by international experts on pediatric nutrition that about 50% of infant calorie intake should be from fats (Aggett et al., 1991 (Aggett et al., , 1994 European Union, 1996; Koletzko et al., 2000; WHO/FAO, 1994) . The model assumes that infants ages 0-1 year require 110 kcal/kg body weight for normal growth, based on the range of 100-120 kcal/kg reported by Tigges (1997) . The age-specific requirement for calories from fats is estimated by multiplying 110 kcal/kg times 50th percentile male body weight, and the amount of calories from breast milk or formula fats is approximated at 8.99 kcal/g fat (Tigges, 1997) , assuming 3.5% breast milk fat content based on measurements by Butte et al. (1984) . Figure 4 illustrates that full-time breast-feeding provides the recommended amount of dietary fat intake to satisfy the child's caloric needs through age 3 months, then additional sources of dietary fats are needed. This is in part due to reductions in breast milk fat content and milk fat intake per body weight as full-time breastfeeding continues (Dewey and Lonnerdal, 1983) . In contrast, Figure 5 illustrates that fat intake rates (from vegetable fats) reported by Koletzko et al. (2000) for commercial baby formulas are more consistent over the first year of life. However, baby formulas contain a lower percentage of fats compared to breast milk and therefore technically require supplementation even at age 1 month in order to meet the recommended fat calorie intakes for children. The underlying data and calculation methods for Figures 4 and 5 are presented in the Supplementary Tables A-2 and A-3.
The model integrates as a default assumption that 50% of the infant caloric intake during the first year of life occurs as breast milk intake and/or vegetable fats from baby formula or other fat sources other than animal fats. Current nutritional recommendations indicate that fats from cow's milk and other animal fats are not recommended during the first year of life (Koletzko et al., 2000) . Children ages 6-12 months are reported to have a relatively high per capita intake rate of 111 grams per kilogram body weight per day for dairy products (USEPA, 2002a) , but such intake from infant formulas is likely to represent skim milk if typical label directions are followed.
The default PCDD/F concentrations in breast milk fat are the mean values reported by Wittsiepe et al. (2004) , which correspond to a relatively large population sample taken between the years 2000 and 2003 in urban Germany ( Supplementary Table A -4) . Little data are available concerning PCDD/Fs in commercial baby formulas; however, fats added to baby formulas are those of vegetable origin which contain far lower PCDD/F content compared to breast milk, cow's milk, or other animal fats (Tigges, 1997) . The default PCDD/F concentrations for formula fats ( Supplementary Table  A -5) are based on the 0.21 pg TEQ/g weighted mean estimate of JECFA (2001) for all fats and oils, and due to lack of published congener profile data on baby formula fats, this total TEQ estimate was assumed to follow the congener pattern for the mean value trends in breast milk reported by Wittsiepe et al. (2004) . These default assumptions for PCDD/Fs are consistent with the limited data on baby formulas reported in the preliminary National Health and Nutrition Examination Survey (NHANES) data set (CDC, 2005) FIG. 4. Child fat intake from breast milk and other sources versus age from birth to 12 months. Fat intake from breast milk for full-time breast-fed infants from birth through 12 months based on data from Dewey and Lonnerdal (1983) and Neville et al. (1988) and from other fat intake needed to maintain the recommended 50% of caloric intake requirements as fats (Koletzko et al., 2000) as illustrated in Table A -2. Breast milk fat content is reduced after about 4 months of full-time breast-feeding, and intake of fats from other sources is subsequently needed to maintain the recommended percentage of fat intake.
FIG. 5.
Child fat intake from baby formula and other sources versus age from birth to 12 months. Fat intake from baby formula based on measurements reported by Koletzko et al. (2000) and from other fat intake needed to maintain 50% of caloric intake requirements as fats (Koletzko et al., 2000) as illustrated in Table A -3. Formula fat intake is more uniform than for breast-fed infants and requires supplementation with other dietary fats soon after birth in order to maintain optimal child growth, if one follows the 50% dietary intake as fat recommendation. Table 1 presents the congener-specific TEQ intake rates for the first 12 months of life under assumptions of either full-time breast-feeding or full-time formula-feeding. These estimates represent the relevant source intake rates for fats (grams fat per kg body weight per day) times the default PCDD/F measurements expressed as TEQ (pg TEQ/g fat), which equals the estimated daily dose in pg TEQ per kilogram body weight per day. For the first year of life, the model conservatively assumes 100% bioavailability of dioxins present in breast milk and formula fats.
CHILD DIOXIN INTERNAL DOSE MODEL
For children between ages 1 and 7 years, the per capita dietary intake rates for the eight standard food categories reported for children (USEPA, 2002a) are utilized as default data for the model. The 50th percentile age-specific intake rates are estimated for fruits, vegetables, grains, meats, eggs, dairy, fish, and fats or oils as summarized by Williams et al. (2003) and USEPA (2002a) . The estimated PCDD/F TEQ intakes for North America as estimated by JECFA (2001) are utilized, with total TEQ distributed across congener TEQ groups based on the patterns presented by the USEPA (2003) for meat, poultry, eggs, dairy products, fats and oils, and fish. Table 2 presents the absorbed daily dose estimates in pg TEQ per kilogram body weight per day derived by multiplying the food category intake rates times the corresponding TEQ content and applying a bioavailability assumption of 50%. This bioavailability is based on the mass balance study of PCDD/F absorption in human volunteers by Schlummer et al. (1998) , who showed that net absorption in younger individuals (ages 24-36 years) ranged from 42 to 62% for TCDD (average 49.3%). Schlummer et al. (1998) showed similar net absorption trends for the pentachlorinated PCDD/Fs that comprise most of the background TEQ in blood lipid and lower net absorption for hepta-and octa-chlorinated PCDD/Fs.
Module 3: Child Soil Pathway Intake Parameters
The model is designed to allow users to enter their own sitespecific PCDD/F congener TEQ data that represent average and/or upper bound soil concentrations applicable to child resident exposures. Environmental PCDD/F intake parameters in the model are based on the detailed literature review and probabilistic risk analysis regarding PCDD/F intakes from urban residential scenario recently reported by Paustenbach et al. (2006) and are summarized in the Supplementary Table A-6. The probabilistic analysis provided 95th percentile values for PCDD/F intake via incidental soil ingestion and dermal contact as represented by age-specific dose constants that approximate absorbed doses after being multiplied by the assumed soil TEQ concentration and a relative bioavailability factor according to Equation 1 and is subsequently summed across all congener TEQ groups:
where D abs is absorbed congener dose (pg TEQ/kg body weight/day), C soil is congener concentration in soils (pg TEQ/ kg soil [ppt], DC soil is age-specific dose constant from probabilistic risk assessment which approximates the 95th percentile absorbed dose from soil ingestion and dermal contact in an urban residential scenario (pg/kg body weight/ day per pg/kg in soil) based on Paustenbach et al. (2006) , and Note. All scenarios assume that infant ingests 50% of caloric intake requirements from fat, and the fat not corresponding to breast milk or formula is assumed to come from solid foods with a lipid TEQ comparable to that reported by JECFA (2001) for vegetable fats and oils. No intake of meats, fish, or dairy is included based on current nutritional guidelines for 0-to 12-month-old infants (Tigges, 1997) . Dioxin bioavailability is assumed to be 100%. Congener-specific lipid TEQ concentrations for breast milk are from Wittsiepe et al. (2004) and for formula are based on JECFA (2001) TEQ of 0.21 for vegetable oils and assumed 4% fat content for baby formula. Formula and breast milk fat doses (grams milk fat/kg/day) are based on measured values of Dewey and Lonnerdal (1983) , Koletzko et al. (2000) , and Neville et al. (1988) . (2001) for vegetable products were assumed to apply also to fruits and grains, and all estimates are those for North America except for vegetable products (Western Europe estimate used) and fats and oils (estimate for all countries assessed). Because there were no data for fruits, vegetables, and grains, the average congener TEQ fractions for the other food items were used. Dietary daily doses are calculated as absorbed doses, assuming 50% bioavailability for all food types to adjust for dioxin losses during preparation and cooking as well as intestinal absorption, except 100% assumed for children under 1 year. RB soil is congener-specific relative bioaccessibility compared to the baseline assumption of 50% bioavailability for TCDD (a factor of 1.0 for all tetra and penta congeners, 0.6 for HxCDD/Fs, 0.4 for HpCDD/Fs, and 0.3 for OCDD/F). The relative bioavailability factors (relative to TCDD) adjust for the known tendency of the higher chlorinated PCDD/Fs to adhere more tightly to soils and to be more poorly absorbed by oral and dermal routes relative to TCDD (Birnbaum and Couture, 1988; Norback et al., 1975; Ruby et al., 2002; reviewed in Paustenbach et al., 2006) . These relative bioavailability factors are listed in the Supplementary Table A-6. Three hypothetical data sets for soil PCDD/Fs used for model illustration are contained in the Supplementary Table A-7. The first data set contains a soil PCDD/F pattern consistent with contamination from a 2,4,5-T manufacturing site (Wenning et al., 1993) (proportions by congener) dominated by tetra-, penta-, and hexa-CDD/F TEQ concentrations and having a total TEQ of 100 ppt. The second soil data set contains a higher magnitude of total TEQ concentration (1000 ppt) and a PCDD/ F pattern consistent with municipal soil waste incineration that is dominated by penta-to hepta-CDD/F TEQ concentrations (Wenning et al., 1993) . The third soil data set contains a total TEQ concentration of 1000 ppt TEQ that is dominated by the hepta-and octa-chlorinated congeners which exhibit considerably lower bioavailability compared to the lower chlorinated PCDD/Fs. This pattern is consistent with PCDD/F contamination of pentachlorophenol (Wenning et al., 1993) .
The age-specific dose constant based on the 95th percentile of exposure from the probabilistic risk assessment was estimated using the exposure parameter distributions presented in the Supplementary Table A -6 and the methods for estimating soil ingestion and dermal contact for an urban residential scenario as presented in Paustenbach et al. (2006) .
The model calculates the internal dose (i.e., the absorbed blood lipid TEQ concentration) by multiplying the 95th percentile soil exposure factor times the congener-specific soil TEQ concentration and the relative bioavailability factor. The absorbed doses estimated for each of the three example soil data sets are summarized in Table 3 .
Module 4: Child Toxicokinetic Parameters and Cumulative
Internal Dose Algorithms Table 4 provides a summary of the default toxicokinetic parameters not described above that are integrated into the model. These include the estimated average congener-specific lipid TEQ concentration at birth, empirical estimates of congener-specific elimination rates during age 0-1 year, and the empirical rate of increase in congener half-life through age 7 years. Table 4 also provides the calculated elimination rate constants that are integrated into the model for each 12-month period through age 7 years.
An estimate of average blood lipid TEQ for each congener at birth is required in order to properly cumulate the PCDD/F internal doses in the model. Three reports examined either cord blood lipid TEQ concentrations at birth (Abraham et al., 1998; Schecter et al., 1998) or adipose TEQ concentrations from stillborn infants (Kreuzer et al., 1997) , of which the highest average was that of Kreuzer et al. (1997) . The average congener-specific TEQ concentrations across the three stillborn infants and an infant that died 3 days after birth were adjusted (multiplied by 0.4) to account for the reduction in background adult internal doses for reproductive-age females between the collection time of the Kreuzer infant data (1991 Kreuzer infant data ( -1992 and the mid-2000#s. This correction factor represents the reduction in average breast milk TEQ for German women sampled in 1986-1991 (Furst et al., 1994) and in (Wittsiepe et al., 2004 . Table 4 provides the mean lipid TEQ estimates by congener that serve as the initial internal dose at birth in the modeled infant.
Half-life values for various ages were estimated based on measurements of PCDD/F half-lives reported for human infants (Kreuzer et al., 1997; Leung et al., 2006) and for young children and adolescents Leung et al., 2005) . These empirical data indicate that the half-lives of PCDD/Fs increase at a rate of about 0.12-0.18 years for every year of advancing age Leung et al., 2005) . The congener-specific rate of increase in half-life with age was combined with the estimated PCDD/F congener half-lives determined in infants during the first 12 months of life to provide annual average elimination rate estimates (expressed as first-order rate in days À1 ) for each of the years examined in the model (Table 4 ).
The model algorithms are designed to calculate age-specific PCDD/F TEQ internal doses by incrementally adding the absorbed PCDD/F TEQ doses from each substantial source (dietary and environmental) to the existing internal dose, subtracting the amount eliminated, and adjusting for growthrelated expansion of adipose volume. Inhalation exposures to PCDD/Fs in vapor or house dust forms are assumed to be negligible compared to dietary and soil ingestion/dermal contact routes . In addition, we did not include dioxin-like Polychlorinated biphenyls in our assessment due to a paucity of pharmacokinetic data in children.
The age-specific internal dose (i.e., cumulative blood lipid TEQ concentration) across all congeners at time t (months) through the age of 84 months can be calculated from:
where i is the specific PCDD/F congener (TCDD, TCDF, PeCDD, 4-PeCDF, HxCDD/Fs, HpCDD/Fs, or OCDD/F), t is Congener half-lives based on Leung et al. (2006) as measured in German infants by Abraham et al. (1996; . Estimates were available for only six congeners, so missing congeners (e.g., TCDF and OCDF) with the same number of chlorines as measured congeners (e.g., TCDD and OCDD) were assumed to have the same half-life. c Rate of increase according to Kerger et al. (2006) for TCDD and according to Leung et al. (2005) for PeCDF, HxCDF, and HpCDF. Measurement data were available for only four congeners, so missing congeners (e.g., TCDF, 4-PeCDF) were assigned the same rate as for measured congeners with the same number of chlorines, and OCDD/F were assumed to have the same rate as 1,2,3,4,6,7,8-HpCDD. Half-life in days calculated by multiplying half-life in years times 365, increasing by the congener-specific rate of half-life increase for each 12-month period through age 84 months. e First-order elimination rate calculated as 0.693 divided by half-life in days.
CHILD DIOXIN INTERNAL DOSE MODEL
the age of child (0-84 months), T is the time duration (1 month or 30.4 days), C is the total cumulative TEQ concentration at the specific age (pg/g fat), C i,t is the concentration of the specific congener at the specific age (pg/g fat).
At t ¼ 0, C i,0 ¼ concentration of the specific congener at birth, K i,t is the first-order elimination rate constant of the specific congener at the specific age (per day), X i,t is the TEQ intake of the specific congener from breast milk at the specific age which ranges from 0 to 12 months (pg/kg/day), Y i,t is the TEQ intake of the specific congener from formula at the specific age which ranges from 0 to 12 months (pg/kg/day), S i,t is the TEQ intake of the specific congener from soil (oral and dermal) at the specific age which ranges from 7 to 84 months (pg/kg/day), D i,t is the TEQ intake of the specific congener from food at the specific age which ranges from 13 to 84 months (pg/kg/day), W i,t is the body weight of child at the specific age which ranges from 0 to 84 months (kg), and F i,t is the fat mass of child at the specific age which ranges from 0 to 84 months (g). Figure 6 illustrates the model output for varied breastfeeding durations, ranging from 0 (full-time formula-feeding) to 12 months of full-time breast-feeding for children subsequently exposed to environmental soil TEQ concentrations of 100 ppt (data set #1). For breast-feeding durations of 3, 6, and 12 months, the peak internal dose occurs within the first 4 months and ranges from about 35 ppt TEQ (3 months duration) to 40 ppt TEQ (6 or 12 months). A relative plateau in internal dose is achieved after about 24 months of age for all three breast-feeding durations, although a continued gradual rate of depuration is apparent between 24 and 84 months under the 12 months full-time breast-feeding assumption. The TWA internal dose from birth through age 7 years (84 months) increases at a linear rate of 0.5 ppt TEQ per month of full-time breast-feeding in this scenario. Figure 6 also shows that the modeled internal doses among full-time formula-fed infants are lowered during the rapid growth phase of the first 12 months of life and, subsequently, begin accumulating higher TEQ internal doses from background dietary sources (primarily dairy) in the second 12 months of life. A slower rate of accumulation occurs after 24 months of age, reaching an approximate plateau in TEQ internal dose after about 60 months of age. The TWA internal dose for strictly formula-fed infants is about fourfold lower than that for 12 months of full-time breast-feeding, differing by about 7 ppt TEQ in blood lipid according to the modeled assumptions for this scenario. After 24 months of age, the formula-fed and 3-or 6-month breast-feeding duration groups show similar average internal doses (4.5, 5.3, and 6.2 ppt, respectively), while the average for 12 months breast-feeding is considerably higher at 10.2 ppt (Fig. 6) . Figure 7 illustrates the model outcome for a constant breastfeeding duration (3 months full time) and varied ingestion and dermal contact exposures to dioxins in soils. Data set #1 represents exposures to soils with 100 ppt TEQ in a pattern dominated by TEQ from lower chlorinated congeners (mainly TCDD) and corresponds to a TWA internal dose of 7.4 ppt and a plateau after 24 months of age averaging 5.3 ppt. Data set #2 represents exposures to soils with 1000 ppt TEQ in a pattern dominated by TEQ from penta-, hexa-, and hepta-chlorinated congeners and corresponds to a TWA internal dose of 8.5 ppt and a plateau after 24 months of age averaging 6.5 ppt. Data set #3 represents exposures to soils with 1000 ppt TEQ in a pattern dominated by TEQ from higher chlorinated congeners (hepta-, and octa-chlorinated) and corresponds to a TWA internal dose of 7.9 ppt and a plateau after 24 months averaging 5.7 ppt. Note that the difference between data sets #2 and #3, which have the same soil TEQ concentration, relates to the lower relative bioavailability of the higher chlorinated congeners (e.g., hepta-and octaCDD/Fs) that are more prevalent in data set #3.
MODEL APPLICATION
MODEL VALIDATION
Two reports by German investigators provide individual infant PCDD/F internal dose data following specified breastfeeding durations. Kreuzer et al. (1997) reported data for nine FIG. 6 . TEQ dose versus age for varied breast-feeding durations and soil TEQ of 100 ppt (data set #1). Modeled age-specific blood lipid TEQ profiles are shown for breast-feeding durations of 0, 3, 6, and 12 months, and TWA dose estimates are provided for each example. Formula-fed infants (0 month breast-fed) are predicted to show a drop in blood lipid TEQ during the rapid growth phase from birth to 12 months of age, while breast-fed infants show a rapid accumulation to peak values within 6 months and a rapid reduction between 6 and 24 months of age. All infants reach a relative plateau in body burden after 24-36 months. Data for soil TEQ concentrations are shown in Table A -7 with corresponding age-specific absorbed TEQ dose illustrated in Table 3 . Breast milk and formula dioxin concentrations are shown in Tables A-4 and A-5, with corresponding age-specific TEQ intake rates illustrated in Table 1 . Age-specific dietary TEQ intake rates are illustrated in Table 2. 232 KERGER ET AL. infants who died of sudden infant death syndrome in the mid-1990#s who were breast-fed 0.2-4.4 months before sampling. Abraham et al. (1998) reported data for six infants born in 1992-1995 who were breast-fed 1.6-7.4 months, four of which were first born and two second born to the same mother. Since Kreuzer et al. (1997) did not collect breast milk PCDD/F concentration data, our validation exercise was initially done by applying the model algorithms for predicting internal doses from the reported breast-feeding durations and sampling times using the average breast milk PCDD/F concentrations for 526 German mothers sampled in 1986-1991 by Furst et al. (1994) . Abraham et al. (1998) reported breast milk concentrations for each of the six infants studied, showing PCDD/F TEQ concentrations (11-22 pg TEQ/g lipid) which were lower than the average value of 34 pg TEQ/g lipid reported by Furst et al. (1994) . Thus, separate model runs were also made using the specific early breast milk concentrations for each of these six infants.
Table 5 provides a validation exercise for the model internal dose predictions relating to varied durations of breast-feeding based on published internal dose data for 15 German infants sampled in the early to mid-1990#s. The assumed breast milk PCDD/F concentration and congener distribution used in the model was based on the average (34 pg TEQ/g lipid) reported for 526 German mothers sampled in 1986-1991 by Furst et al. (1994) . The modeled infant TEQ values for the nine Kreuzer infants, the six Abraham infants, and the 15 combined (respective averages 48.3, 35.3, and 43.1 pg/g) were 2.1-to 3.5-fold higher than the measured TEQ values (respective averages 13.7, 16.7, and 14.9 pg/g). Birth order was not reported for the nine breast-fed infants of Kreuzer et al. (1997) , but four of the six infants examined by Abraham et al. (1998) were first-born and two were second-born infants (B1-2 and B2-2). A greater margin of difference was observed for the shortest breast-feeding durations (e.g., less than 2 months) and for the two second-born infants. Since individual-specific breast milk PCDD/F concentrations were reported by Abraham et al. (1998) , the model was run for each infant using the specific early breast milk TEQ concentration. Table 5 shows that modeled infant TEQ values (averaging 17.2 pg/g) are quite consistent with the measured TEQ values (averaging 16.7 pg/g) across the six infants studied by Abraham et al. (1998) . The predicted values for individual infants varied from the measured values by only 19-41%.
Although data for model validation in this case are quite limited, Table 5 illustrates that the modeled internal doses for 15 infants with different breast-feeding durations are generally about two-to threefold higher than the measured internal doses for children up to about 1 year old. To some degree, this tendency toward overestimation may be related to the use of breast milk PCDD/F concentrations in an earlier era (1986) (1987) (1988) (1989) (1990) (1991) than that for the infant internal dose sampling (about 1992-1995) . Concurrent breast milk concentrations were apparently somewhat lower for the six Abraham infants, but we chose to use breast milk data from the most robust survey of German mothers preceding the infant sampling dates. Shorter durations of breast-feeding (e.g., < 2 months) were associated with greater margins of internal dose overstatement by the model for unknown reasons. Also, the second-born infants reported by Abraham et al. (1998) showed a greater margin of internal dose overstatement due in part to the fact that the modeled breast milk concentration of 34 pg TEQ/g lipid from Furst et al. (1994) overstated the measured breast milk levels by about two-to threefold for infants B1-2 and B2-2 (Abraham et al., 1996 (Abraham et al., , 1998 . Individual-specific model runs for the six infants with early breast milk TEQ concentrations showed predicted values remarkably close to the measured infant internal doses (within 19-41%, for predicted vs. measured, Table 5 ). It should be noted that individual-specific factors that likely affect infant internal doses were not included in the model, such as actual body weight and growth pattern, gender, breast-feeding pattern, and specific infant diet from weaning until blood sampling at age 11.3-12.1 months. Since breast milk exposures generally dominate the peak and TWA internal FIG. 7. TEQ dose versus age for 3-month breast-feeding and varied soil TEQ (data sets #1, #2, and #3). Modeled age-specific blood lipid TEQ profiles are shown for a child breast-fed for 3 months and exposed to one of three residential soil exposure scenarios (data sets #1, #2, or #3), and TWA dose estimates are provided for each example. Following rapid accumulation of blood lipid TEQ from breast-feeding, a relatively rapid pattern of depuration occurs and reaches a plateau after 24 months in each example. TWA body burdens are similar for each case, despite a 10-fold difference in soil TEQ concentrations. Data for soil TEQ concentrations are shown in Table A -7 with corresponding age-specific absorbed TEQ dose illustrated in Table 3 . Breast milk and formula dioxin concentrations are shown in Tables A-4 and A-5, with corresponding age-specific TEQ intake rates illustrated in Table 1 . Age-specific dietary TEQ intake rates are illustrated in Table 2. CHILD DIOXIN INTERNAL DOSE MODEL dose in young children, this limited validation exercise would reasonably support the use of this model for risk assessment purposes, mindful of the fact that the model is an inexact tool, the accuracy of which largely depends on proper concordance of the input data with the characteristics of the population of interest.
We were unable to locate data on background internal doses in young children after infancy (e.g., 12-84 months old) that provided adequate information on breast-feeding and other dietary exposures to allow for testing of the current model. However, the TCDD half-life information utilized in the current model was based on data from a cohort of children and adolescents exposed during the trichlorophenol reactor explosion incident in Seveso, most of whom were under age 10 years at the time of exposure . Also, the predicted child internal doses at age 7 are less than twofold higher than those for Australian children averaging 10 years old (Harden et al., 2004) . The other PCDD/F congener halflives from Leung et al. (2006) were based on the unique mass balance data set for two German infants that included specific assessments of breast milk and dietary intakes along with the internal dose measurements (Abraham et al., 1996 (Abraham et al., , 1998 . However, similar PCDD/F mass balance data sets have not been published for older children to our knowledge. We recommend further validation testing of the model as appropriate childhood internal dose data become available.
DISCUSSION
This report expands on a preliminary age-dependent half-life model for PCDD/Fs in infants and young children (Kerger et al., 2007) by incorporating more detailed empirical data on model parameters and adapting the algorithms into a userfriendly spreadsheet program that allows for input of sitespecific PCDD/F congener data in environmental media including soils, foods, and breast milk. The current model includes empirical estimates of infant half-lives and rates of increase in half-lives with age for PCDD/F congeners Leung et al., 2006) , more current and detailed data on monthly child body weight/body fat mass (CDC, 2000) and body weight-scaled dietary fat intakes during the period of peak internal dose shifts (ages 0-2 years), and robust recent data on background breast milk dioxin concentrations (Wittsiepe et al., 2004) . Data on relative bioavailability of higher chlorinated PCDD/Fs compared to TCDD were also incorporated (Birnbaum and Couture, 1988; Norback et al., 1975; Ruby et al., 2002) . The model also incorporates recent food dioxin concentrations for North America estimated by JECFA (2001) and empirical age-specific intake rates for breast milk, other foods (USEPA, 2002a; Williams et al., 2003) , and for age-specific dermal contact and ingestion exposures to PCDD/F contaminated soils .
The model produces a profile of blood lipid TEQ concentration versus age through 84 months and allows for calculation of the TWA child internal dose during the first 7 years of life ( Figs. 6 and 7) . Estimates of peak internal dose and TWA internal dose are considered the most important dose metrics for determining the human health risks of dioxins (USEPA, 2003) . Thus, comparison of the output from this simple model to benchmark doses based on toxicity studies and/or background exposures may be considered more scientifically relevant than the currently used or suggested USEPA approaches based on daily dose estimates (USEPA, 1989 (USEPA, , 2003 . A somewhat similar model was developed by USEPA (2002b) for evaluation of child internal doses of lead, another persistent pollutant with health risks that are difficult to assess based on daily dose estimates. The proposed dioxin child This modeling assumed PCDD/Fs intake from breast milk based on the concentration (total TEQ of 34.14 pg/g fat) reported by Furst et al. (1994) with no depuration. Distribution of congeners was TCDD (9.37%), TCDF (0.50%), PeCDD (29.58%), 4-PeCDF (39.10%), HxCDD/Fs (20.00%), HpCDD/Fs (1.38%), and OCDD/F (0.06%). The burden at birth (10.20 pg TEQ/g fat) assumed the average of three stillborn infants and one infant that died 3 days after birth from Kreuzer et al. (1997) . c This modeling assumed PCDD/Fs intake from breast milk based on the measured concentrations in the corresponding mothers reported by Abraham et al. (1998) with no depuration. The concentrations (total TEQ pg/g fat) were 19.7 for infant B1-1, 11.9 for infant B1-2, 22.2 for infant B2-1, 15.6 for infant B2-2, 11.8 for infant B3, and 10.9 for infant B4. All breast milk TEQ measurements were taken from the mother 1 month after birth of the specific child, except B1-1, which was taken 1 month before childbirth. The proportions of PCDD/Fs congeners were assumed to be similar to those reported by Furst et al. (1994) . The burden at birth (10.20 pg TEQ/g fat) assumed the average of the four stillborn infants from Kreuzer et al. (1997) . 234 KERGER ET AL. internal dose model similarly integrates the chemical uptake from important sources and utilizes empirical human toxicokinetic data to model the internal dose versus time profile in young children. Similar to the safe internal dose benchmarks identified through scientific consensus among experts in the toxicology of lead compounds (USEPA, 2002b), we recommend that similar benchmarks be identified for evaluating the health risk implications of the dioxin child internal dose model. Benchmarks based on human clinical studies and perhaps also on the range of current background blood lipid concentrations may be reasonably considered for comparison to the modelpredicted results for children through age 7 years.
Possible benchmarks for comparison of the model-estimated peak internal dose might rely on the low-effect levels for TCDD-induced chloracne in children of 828 ppt identified by Mocarelli et al. (1991) and the approximate threshold of 800-1000 ppt for mild chloracne and for liver enzyme induction among Viennese laboratory workers accidentally exposed to TCDD (reviewed in Guzelian et al., 2006) . Dividing these human low-effect/no effect levels of approximately 800 ppt by a safety factor of 10 results in a benchmark internal dose of 80 ppt in blood lipid for peak exposures that are unlikely to pose an acute health hazard in human infants. Accordingly, breast milk exposures associated with peak blood lipid levels exceeding 80 ppt might provide a rationale for actions to limit breast-feeding exposures.
The TWA internal dose estimates from the model may be compared to estimates of current background population internal doses of PCDD/Fs among younger reproductive-age females. Ferriby et al. (2007) summarized the NHANES study findings for younger adult females (ages 20-34) with a median TEQ in blood lipid at about 10 ppt and the 95th percentile at 23 ppt. Accordingly, model-estimated TWA internal doses that exceed 23 ppt TEQ might define a benchmark for taking corrective actions to avoid sources of excessive exposure to younger children. Further research on health-based benchmarks based on TWA internal dose estimates in human children and young adults is needed.
These modeling exercises illustrate that the much shorter half-life of dioxins in young children (e.g., 0.27-0.46 years) are capable of rapidly moderating internal doses from background dietary and environmental intakes, translating to average internal doses from age 0 to 7 that are well below those for adults who exhibit a much longer half-life (e.g., 7-11 years). An earlier modeling analysis of infant dioxin internal doses by Lorber and Phillips (2002) came to similar conclusions using TCDD as a surrogate for TEQ from all PCDD/Fs in breast milk. Breast-feeding is the dominant factor for dioxin internal dose in young children (Fig. 6) . The longest assumed duration of full-time breast-feeding (12 months) showed a predicted TWA internal dose of 13.9 ppt, which is about twofold lower than background PCDD/F internal doses around 19-30 ppt TEQ in the blood lipid of adults in the United States and Europe (Aylward and Hays, 2002; Ferriby et al., 2007; Hays and Aylward, 2003; Lorber, 2002; USEPA, 2003) and is about fourfold higher than the background PCDD/F internal doses of 3.9 ppt TEQ in the blood lipid of children with an average age of 10 years in Australia (Harden et al., 2004) . Under more typical durations of breast-feeding (i.e., 3-6 months), the TWA internal doses are lower (7.3-9.7 ppt) and approach a similar plateau as for formula-fed infants after about 24 months. These modeled TEQ internal doses are approximately two-to fourfold below estimated current adult internal dose estimates (Aylward and Hays, 2002; Ferriby et al., 2007; Hays and Aylward, 2003; Lorber, 2002; USEPA, 2003) and less than twofold higher than current internal dose estimates for children averaging 10 years old (Harden et al., 2004) .
The model also allows evaluation of dioxin uptake from soils via dermal contact and soil ingestion. The algorithms for the internal dose via soil ingestion and dermal contact were adapted from a detailed probabilistic risk assessment approach recently reported by Paustenbach et al. (2006) . This probabilistic risk assessment methodology is based on comprehensive assessment of central tendency data and uncertainties for the key exposure factors in an urban residential setting (see Supplementary Table A -6) ; it does not incorporate data or assumptions regarding child pica or possible indirect exposure pathways (e.g., site-related impacts on fish or livestock) other than soil ingestion and dermal contact . However, the 95th percentile estimates for PCDD/F uptake via soil ingestion and dermal contact used in the current model are considered appropriate to capture the most likely upper bound soil exposures for young children in an urban residential setting.
Three different soil PCDD/F patterns are used to illustrate the impact of 95th percentile soil exposures on the TEQ internal dose profile in young children (Fig. 7) . Despite a 10-fold difference in soil TEQ between data sets #1 and #2, the difference in TWA internal dose was only 1.2 ppt and during the peak soil ingestion timeframe (ages 3-4 years) differed by less than 2 ppt TEQ. A smaller difference was apparent between data set #1 and #3, despite the same 10-fold difference in soil TEQ concentrations. The muted difference between data set #1 and either #2 or #3 is due to the increasingly prominent presence of higher chlorinated PCDD/F congeners in each data set ( Supplementary Table A-7) ; the model accounts for the lower relative bioavailability of hepta-and octa-chlorinated congeners, and this equates with lower TEQ internal dose in the child.
The current model is not comprehensive of all PCDD/F sources and has certain weaknesses. First, it does not include algorithms for all plausible direct and indirect PCDD/F exposure pathways. As discussed by Paustenbach et al. (2006) , most of the additional exposure pathways are either negligible compared to uptake via dietary and soil pathways (e.g., inhalation or homegrown vegetable pathways) or they are unique to certain populations whose consideration would greatly skew the central tendency uptake estimates (e.g., subsistence farmer CHILD DIOXIN INTERNAL DOSE MODEL or fisher groups). Thus, one must cautiously evaluate possible contributions from other relevant exposure pathways when evaluating the outputs from the current model. Second, the current model does not attempt to include dioxin-like polychlorinated biphenyls due to the paucity of toxicokinetic data for these congeners in humans. Third, the current model does not attempt to account for cumulative impacts of soil exposures on adult female/breast milk dioxin concentrations. However, application of the age-dependent half-life model suggests that shorter PCDD/F half-lives during early childhood and adolescence may greatly attenuate contributions to the accumulated adult internal dose (and adult breast milk concentration) from soil-related exposures in reproductive-age females (Richter et al., 2006) . Fourth, the estimated half-lives included in the current model are empirical estimates and surrogate values that require further validation based on human studies Leung et al., 2006) . And fifth, the current model does not include an algorithm to account for the depuration of breast milk PCDD/F concentrations with longer breast-feeding durations due to the paucity of available data and the uncertainties on this topic. As additional data become available to resolve these issues, adjustments should be made to increase the accuracy of the model.
In conclusion, the proposed child dioxin internal dose model is an important step toward identifying a useful risk assessment approach for noncancer effects of PCDD/Fs relating to exposures during early childhood. It is hoped that the current approach can be further developed and refined to become a useful risk assessment tool as was the case for the Integrated Environmental Uptake Biokinetic Model adopted by USEPA (2002b). Further, it is important to assess the potential health risks of PCDD/Fs by taking into account the most recent empirical findings in humans. The age-dependent half-life findings provide some very important scientific caveats regarding past concerns about exposures from breast-feeding and soil exposures.
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